Hematologic Malignancy
Mature B-Cell Neoplasm
CI-CAN-00003258Explore in graph →
HematologicNon-malignant1,787 active trials44 approved drugs119 evidence items
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00003258Explore in graph →
Clinical trials
6,664 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04309981 | Clinical Trial Using Humanized CART Directed Against BCMA (ARI0002h) in Patients With Relapsed/Refractory Multiple Myeloma to Proteasome Inhibitors, Immunomodulators and Anti-CD38 Antibody. | unknown | Phase 1 / Phase 2 | 73 | Sara V. LatorreOTHER | 1 | Aug 28, 2023 | clinicaltrials |
| NCT05673447 | The Study of Anti-CD19 CAR NK Cells in the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma | unknown | Early Phase 1 | 12 | Changhai HospitalOTHER | 1 | Aug 28, 2023 |
| NCT06007989 | Assessing the Relationship Between Hypoxia and the Immune Environment in Myeloma Patients (CHIME)(CHIME) | unknown | — | 10 | The Christie NHS Foundation TrustOTHER | 1 | Aug 23, 2023 | clinicaltrials |
| NCT02471391 | ABT-199 & Ibrutinib in Mantle Cell Lymphoma (AIM)(AIM) | unknown | Phase 2 | 37 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Aug 21, 2023 | clinicaltrials |
| NCT05990985 | The Efficacy and Safety of the RCMOP Sequential Therapy as a First-line Treatment for Patients With Intermediate-to-high Risk Diffuse Large B-cell Lymphoma Who Had Incomplete Remission. | unknown | N/A | 20 | The First Hospital of Jilin UniversityOTHER | 1 | Aug 18, 2023 | clinicaltrials |
| NCT05995808 | Cyclin D1 as a Prognostic Factor in Multiple Myeloma and Its Association With the Immunological Prognostic Factor PDL1 and Clinical and Biochemical Lab Tests | unknown | N/A | 30 | Sohag UniversityOTHER | 0 | Aug 16, 2023 | clinicaltrials |
| NCT05974085 | XPO-1 in Combination With RCHOP for DH/TH Lymphoma | unknown | Phase 2 | 10 | Zhejiang Cancer HospitalOTHER | 1 | Aug 3, 2023 | clinicaltrials |
| NCT05975164 | the Real World Study of Orelabrutinib in the Treatment of CLL/SLL | unknown | — | 50 | Shandong UniversityOTHER | 0 | Aug 3, 2023 | clinicaltrials |
| NCT05005299 | Venetoclax in Combination With Non-myeloablative Conditioning Allogeneic Haematopoietic Stem Cell Transplantation(VICTORY) | unknown | Phase 1 | 18 | Melbourne HealthOTHER | 1 | Aug 1, 2023 | clinicaltrials |
| NCT05871684 | A Combination Study of CAR-T Therapy in r/r B-NHL | unknown | Phase 2 | 48 | Ruijin HospitalOTHER | 1 | Aug 1, 2023 | clinicaltrials |
| NCT05887726 | Zanubrutinib Combined With R-CHOP Regimen in the Treatment of Newly Diagnosed DLBCL With High-risk Factors | unknown | Phase 2 | 30 | Liaoning Cancer Hospital & InstituteOTHER | 1 | Jul 27, 2023 | clinicaltrials |
| NCT05964270 | Telemonitoring Among Patients With Multiple Myeloma(ITUMM) | unknown | N/A | 150 | IsalaOTHER | 1 | Jul 27, 2023 | clinicaltrials |
| NCT05020392 | Autologous Cells Derived Anti-CD19 CAR-Engineered T Cells With Concurrent BTK Inhibitor for B Cell Lymphoma | unknown | Phase 3 | 24 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jul 25, 2023 | clinicaltrials |
| NCT04143932 | Multiple Myeloma Turkish Prospective Patient Registry(THD-MM-Reg) | unknown | — | 1,000 | Turkish Hematology AssociationOTHER | 1 | Jul 18, 2023 | clinicaltrials |
| NCT02825836 | Phase I/II, FIH, Dose Escalation Trial of TL-895 and Expansion of TL-895 Monotherapy and Combination Therapy With Navtemadlin in Tx-Naïve and R/R CLL/SLL Subjects | unknown | Phase 1 / Phase 2 | 130 | Telios Pharma, Inc.INDUSTRY | 7 | Jul 13, 2023 | clinicaltrials |
| NCT04836871 | Double Filtration Plasmapheresis Combined With Chemotherapy | unknown | Phase 1 | 20 | Fuling ZhouOTHER | 1 | Jul 13, 2023 | clinicaltrials |
| NCT05932173 | A Study of Novel Anti-CD19 CAR-T in Patients With r/r B-Cell Malignancies | unknown | Phase 1 / Phase 2 | 60 | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of ChinaOTHER | 1 | Jul 11, 2023 | clinicaltrials |
| NCT05940051 | Prospective Clinical Study of ZPR Regimen in Relapsed/Refractory Diffuse Large B-cell Lymphoma | unknown | Phase 2 | 35 | Peng LiuOTHER | 1 | Jul 11, 2023 | clinicaltrials |
| NCT05940064 | Prospective Clinical Study of ZPR Regimen in Elderly Treatment-naive Diffuse Large B-cell Lymphoma | unknown | Phase 2 | 30 | Peng LiuOTHER | 1 | Jul 11, 2023 | clinicaltrials |
| NCT03695744 | Daratumumab in Combination With Bortezomib and Dexamethasone in Newly Diagnosed Transplant Ineligible Multiple Myeloma | unknown | Phase 2 | 27 | Singapore General HospitalOTHER | 1 | Jul 10, 2023 | clinicaltrials |
| NCT04763083 | First in Human Study of NVG-111 in Relapsed/Refractory ROR1+ Malignancies | unknown | Phase 1 | 90 | NovalGen Ltd.INDUSTRY | 1 | Jul 7, 2023 | clinicaltrials |
| NCT05715606 | Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r DLBCL Clinical Research | unknown | Early Phase 1 | 18 | Anhui Provincial HospitalOTHER_GOV | 1 | Jul 5, 2023 | clinicaltrials |
| NCT04814615 | A Diagnostic Study of CD38-Targeted ImmunoPET of Myeloma | unknown | Phase 2 | 60 | Hoag Memorial Hospital PresbyterianOTHER | 1 | Jun 27, 2023 | clinicaltrials |
| NCT05920668 | Phase IV Observational Study of Orelabrutinib in the Treatment of Chronic Lymphocytic Leukemia/Small Cell Lymphoma | unknown | — | 20 | Wang XinOTHER_GOV | 1 | Jun 27, 2023 | clinicaltrials |
| NCT05920876 | A Study of QLS32015 in Patients With Recurrent or Refractory Multiple Myeloma | unknown | Phase 1 | 100 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 27, 2023 | clinicaltrials |
| NCT03809780 | Study to Demonstrate Clinical Benefit of Lenalidomide and Dexamethasone(LENDER) | unknown | Phase 2 | 70 | Kosin University Gospel HospitalOTHER | 1 | Jun 22, 2023 | clinicaltrials |
| NCT05834426 | Omic Technologies Applied to the Study of B-cell Lymphoma for the Discovery of Diagnostic and Prognosis Biomarkers | unknown | — | 50 | Sociedad de Lucha Contra el Cáncer del EcuadorOTHER | 1 | Jun 22, 2023 | clinicaltrials |
| NCT03641456 | VRD as Induction Followed by VR Maintenance in Patients With Newly Diagnosed High Risk Multiple Myeloma | unknown | Phase 2 | 50 | Sun Yat-sen UniversityOTHER | 1 | Jun 18, 2023 | clinicaltrials |
| NCT05907447 | A Retrospective Study on Extranodal Lymphoma or Lymphoma of Rare Pathological Types | unknown | — | 10,000 | Ruijin HospitalOTHER | 1 | Jun 18, 2023 | clinicaltrials |
| NCT03090659 | LCAR-B38M Cells in Treating Relapsed/Refractory (R/R) Multiple Myeloma(LEGEND-2) | unknown | Phase 1 / Phase 2 | 100 | Nanjing Legend Biotech Co.INDUSTRY | 0 | Jun 12, 2023 | clinicaltrials |
| NCT05899543 | Determining Clinical Study Experiences of Chronic Lymphocytic Leukemia Patients | unknown | — | 500 | Power Life Sciences Inc.INDUSTRY | 1 | Jun 12, 2023 | clinicaltrials |
| NCT05893693 | Assess the Safety and Efficacy of CT0594CP Cells in Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia | unknown | N/A | 12 | Aibin Liang,MD,Ph.D.OTHER | 1 | Jun 8, 2023 | clinicaltrials |
| NCT04578613 | ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLL | unknown | Phase 3 | 218 | Beijing InnoCare Pharma Tech Co., Ltd.INDUSTRY | 1 | Jun 5, 2023 | clinicaltrials |
| NCT05888701 | "Don't Eat me" Signal in Hematological Malignancies: CD24 as New Target to Improve Anti-cancer Immunity. | unknown | — | 30 | University of Milano BicoccaOTHER | 1 | Jun 5, 2023 | clinicaltrials |
| NCT05855122 | Safety and ASCT-related Symptom Burden Optimization of Tocilizumab in ASCT Following HD Melphalan Conditioning for Multiple Myeloma Patients | unknown | Phase 4 | 48 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jun 2, 2023 | clinicaltrials |
| NCT05883709 | A Real-world Study of Tafasitamab in Combination With Lenalidomide in Patients withR/R DLBCL | unknown | — | 15 | Zhao WeiliOTHER | 1 | Jun 1, 2023 | clinicaltrials |
| NCT05874778 | A Multicenter, Phase 2 Study Evaluating the Value of Radiotherapy in Advanced Diffuse Large B-cell Lymphoma Patients With Extranodal Involvement and Large Tumors Undergoing Immunochemotherapy for PET-CT Assessment of Complete Remission | unknown | Phase 2 | 108 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | May 25, 2023 | clinicaltrials |
| NCT05179733 | The Efficacy and Safety of ZR2 Versus R-miniCHOP in the Treatment of Unfit or Frail de Novo Diffuse Large B-cell Lymphoma Patients Aged Older Than or Equal to 70 Years | unknown | Phase 3 | 280 | Ruijin HospitalOTHER | 1 | May 23, 2023 | clinicaltrials |
| NCT05860179 | Examination of Trends in Multiple Myeloma Trial Patient Experiences | unknown | — | 500 | Power Life Sciences Inc.INDUSTRY | 0 | May 23, 2023 | clinicaltrials |
| NCT04923048 | A Safety, Tolerability, Pharmacokinetics and Efficacy Study of GB261 in B-Cell NHL and CLL. | unknown | Phase 1 / Phase 2 | 460 | Genor Biopharma Co., Ltd.INDUSTRY | 1 | May 22, 2023 | clinicaltrials |
| NCT05487651 | Allogeneic NK T-Cells Expressing CD19 Specific CAR in B-Cell Malignancies(ANCHOR2) | unknown | Phase 1 | 36 | Athenex, Inc.INDUSTRY | 1 | May 18, 2023 | clinicaltrials |
| NCT05863845 | Efficacy and Safety of Venetoclax Combined With BEAM Pretreatment in Autologous Transplantation for DLBCL | unknown | N/A | 52 | Ruijin HospitalOTHER | 0 | May 18, 2023 | clinicaltrials |
| NCT05271682 | A Study Evaluating Safety, Tolerability and Clinical Activity of FHND6091 in Patients With Multiple Myeloma | unknown | Phase 1 | 40 | Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd.INDUSTRY | 1 | May 16, 2023 | clinicaltrials |
| NCT05859932 | Assessing Medical Trial Experiences of Hairy Cell Leukemia Patients | unknown | — | 500 | Power Life Sciences Inc.INDUSTRY | 0 | May 16, 2023 | clinicaltrials |
| NCT05857982 | Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Relapsed/Refractory Multiple Myeloma | unknown | Phase 1 / Phase 2 | 20 | Second Affiliated Hospital of Soochow UniversityOTHER | 1 | May 15, 2023 | clinicaltrials |
| NCT05858203 | Inhibition of Che-1/AATF as a New Tool in Multiple Myeloma Treatment(AATF/Che-1) | unknown | — | 150 | Regina Elena Cancer InstituteOTHER | 1 | May 15, 2023 | clinicaltrials |
| NCT05852028 | A Real-world Study of Selinexor-based Regimens for Treatment of Non-Hodgkin Lymphoma | unknown | — | 250 | Ruijin HospitalOTHER | 1 | May 10, 2023 | clinicaltrials |
| NCT02632396 | Ixazomib & Rituximab After Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma in Remission | unknown | Phase 1 / Phase 2 | 12 | Emory UniversityOTHER | 1 | May 9, 2023 | clinicaltrials |
| NCT05816746 | Decitabine and Anti-PD-1 in R/R DLBCL | unknown | Phase 2 | 20 | Chinese PLA General HospitalOTHER | 1 | May 9, 2023 | clinicaltrials |
| NCT04356846 | A Phase I Study of LP-108 in Patients With Relapsed or Refractory B-cell Lymphoma | unknown | Phase 1 | 74 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | May 1, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Aug 28, 2023source: clinicaltrials